Chunzhang Wu

3.0k total citations · 4 hit papers
29 papers, 2.0k citations indexed

About

Chunzhang Wu is a scholar working on Surgery, Infectious Diseases and Epidemiology. According to data from OpenAlex, Chunzhang Wu has authored 29 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Surgery, 9 papers in Infectious Diseases and 5 papers in Epidemiology. Recurrent topics in Chunzhang Wu's work include Urinary and Genital Oncology Studies (16 papers), Bladder and Urothelial Cancer Treatments (16 papers) and Antifungal resistance and susceptibility (9 papers). Chunzhang Wu is often cited by papers focused on Urinary and Genital Oncology Studies (16 papers), Bladder and Urothelial Cancer Treatments (16 papers) and Antifungal resistance and susceptibility (9 papers). Chunzhang Wu collaborates with scholars based in United States, Japan and United Kingdom. Chunzhang Wu's co-authors include Daniel P. Petrylak, Jonathan E. Rosenberg, Thomas Powles, Mary S. Campbell, Nobuaki Matsubara, Maria Matsangou, Guru Sonpavde, Ignacio Durán, Yohann Loriot and Christof Vulsteke and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Chunzhang Wu

28 papers receiving 2.0k citations

Hit Papers

Enfortumab Vedotin in... 2007 2026 2013 2019 2021 2007 2020 2023 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
    2021 670 citations Thomas Powles, Jonathan E. Rosenberg et al. New England Journal of Medicine profile →
  2. Micafungin versus Caspofungin for Treatment of Candidemia and Other Forms of Invasive Candidiasis
    2007 478 citations Peter G. Pappas, Robert F. Betts et al. Clinical Infectious Diseases profile →
  3. EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma
    2020 223 citations Jonathan E. Rosenberg, Srikala S. Sridhar et al. Journal of Clinical Oncology profile →
  4. EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma
    2023 84 citations Jonathan E. Rosenberg, Thomas Powles et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Chunzhang Wu United States 15 831 804 670 661 299 29 2.0k
Carola Arndt United States 23 820 1.0× 308 0.4× 743 1.1× 753 1.1× 699 2.3× 41 2.5k
S. Špánik Slovakia 20 382 0.5× 325 0.4× 337 0.5× 556 0.8× 279 0.9× 79 1.4k
Juan Palou Spain 24 128 0.2× 1.5k 1.9× 645 1.0× 292 0.4× 423 1.4× 84 2.4k
I‐Shiow Jan Taiwan 21 363 0.4× 516 0.6× 484 0.7× 257 0.4× 349 1.2× 61 1.3k
Tsiporah B. Shore United States 27 345 0.4× 114 0.1× 516 0.8× 919 1.4× 252 0.8× 152 2.3k
Hamdi Akan Türkiye 26 602 0.7× 136 0.2× 775 1.2× 555 0.8× 131 0.4× 106 1.8k
David Bodensteiner United States 18 866 1.0× 114 0.1× 771 1.2× 363 0.5× 156 0.5× 35 1.7k
Chiara Cattaneo Italy 25 387 0.5× 71 0.1× 553 0.8× 1.3k 1.9× 89 0.3× 102 2.2k
Hans‐Heinrich Wolf Germany 20 465 0.6× 118 0.1× 480 0.7× 427 0.6× 136 0.5× 42 1.3k
U. Jehn Germany 24 498 0.6× 105 0.1× 569 0.8× 827 1.3× 154 0.5× 125 2.7k

Countries citing papers authored by Chunzhang Wu

Since Specialization
Citations

This map shows the geographic impact of Chunzhang Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chunzhang Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chunzhang Wu more than expected).

Fields of papers citing papers by Chunzhang Wu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chunzhang Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chunzhang Wu. The network helps show where Chunzhang Wu may publish in the future.

Co-authorship network of co-authors of Chunzhang Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Chunzhang Wu. A scholar is included among the top collaborators of Chunzhang Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chunzhang Wu. Chunzhang Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rosenberg, Jonathan E., Thomas Powles, Guru Sonpavde, et al.. (2023). EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma. Annals of Oncology. 34(11). 1047–1054. 84 indexed citations breakdown →
2.
Ono, Makiko, Justine Y. Bruce, Trevor Feinstein, et al.. (2022). Abstract OT1-02-04: Enfortumab vedotin 202: Phase 2 study of enfortumab vedotin for previously treated advanced solid tumors, including breast cancer. Cancer Research. 82(4_Supplement). OT1–2. 2 indexed citations
3.
Powles, Thomas, Jonathan E. Rosenberg, Guru Sonpavde, et al.. (2021). Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. New England Journal of Medicine. 384(12). 1125–1135. 670 indexed citations breakdown →
4.
5.
Rosenberg, Jonathan E., Thomas Powles, Guru Sonpavde, et al.. (2021). 698P Analysis of hard-to-treat subgroups from EV-301: A phase III trial of enfortumab vedotin (EV) vs chemotherapy for previously treated advanced urothelial carcinoma. Annals of Oncology. 32. S710–S711. 2 indexed citations
6.
Rosenberg, Jonathan E., Srikala S. Sridhar, Jingsong Zhang, et al.. (2020). EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma. Journal of Clinical Oncology. 38(10). 1041–1049. 223 indexed citations breakdown →
7.
Bruce, Justine Y., Lajos Pusztai, Fadi S. Braiteh, et al.. (2020). EV-202: A phase II study of enfortumab vedotin in patients with select previously treated locally advanced or metastatic solid tumors.. Journal of Clinical Oncology. 38(15_suppl). TPS3647–TPS3647. 11 indexed citations
8.
Petrylak, Daniel P., Jonathan E. Rosenberg, Ignacio Durán, et al.. (2019). EV-301: Phase III study to evaluate enfortumab vedotin (EV) versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC).. Journal of Clinical Oncology. 37(7_suppl). TPS497–TPS497. 14 indexed citations
9.
Petrylak, Daniel P., Jonathan E. Rosenberg, Ignacio Durán, et al.. (2019). A phase 3 study to evaluate enfortumab vedotin (EV) versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC): EV-301, a trial-in-progress. European Urology Supplements. 18(1). e1836–e1837. 1 indexed citations
10.
Petrylak, Daniel P., Jonathan E. Rosenberg, Junji Yonese, et al.. (2019). EV-301: A phase III trial in progress evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma. Annals of Oncology. 30. ix75–ix76. 2 indexed citations
11.
Rosenberg, Jonathan E., Srikala S. Sridhar, Jingsong Zhang, et al.. (2018). Updated results from the enfortumab vedotin phase 1 (EV-101) study in patients with metastatic urothelial cancer (mUC).. Journal of Clinical Oncology. 36(15_suppl). 4504–4504. 33 indexed citations
12.
Petrylak, Daniel P., David C. Smith, Thomas W. Flaig, et al.. (2018). Enfortumab vedotin (EV) in patients (Pts) with metastatic urothelial carcinoma (mUC) with prior checkpoint inhibitor (CPI) failure: A prospective cohort of an ongoing phase 1 study.. Journal of Clinical Oncology. 36(6_suppl). 431–431. 6 indexed citations
13.
Benjamin, Daniel K., David Kaufman, William Hope, et al.. (2018). A Phase 3 Study of Micafungin Versus Amphotericin B Deoxycholate in Infants With Invasive Candidiasis. The Pediatric Infectious Disease Journal. 37(10). 992–998. 27 indexed citations
14.
Manzoni, Paolo, et al.. (2014). Micafungin in Premature and Non-premature Infants. The Pediatric Infectious Disease Journal. 33(11). e291–e298. 29 indexed citations
15.
Benjamin, Daniel K., Jaime G. Deville, Nkechi Azie, et al.. (2013). Safety and Pharmacokinetic Profiles of Repeated-dose Micafungin in Children and Adolescents Treated for Invasive Candidiasis. The Pediatric Infectious Disease Journal. 32(11). e419–e425. 14 indexed citations
16.
Nucci, Márcio, Elias Anaissie, Robert F. Betts, et al.. (2010). Reply to Koh and Luong and to Shaked et al. Clinical Infectious Diseases. 51(11). 1348–1350. 2 indexed citations
17.
Nucci, Márcio, Elias Anaissie, Robert F. Betts, et al.. (2010). Early Removal of Central Venous Catheter in Patients with Candidemia Does Not Improve Outcome: Analysis of 842 Patients from 2 Randomized Clinical Trials. Clinical Infectious Diseases. 51(3). 295–303. 169 indexed citations
18.
Horn, David L., Luis Ostrosky‐Zeichner, Michele I. Morris, et al.. (2009). Factors related to survival and treatment success in invasive candidiasis or candidemia: a pooled analysis of two large, prospective, micafungin trials. European Journal of Clinical Microbiology & Infectious Diseases. 29(2). 223–229. 52 indexed citations
19.
Pappas, P. G., Márcio Nucci, Deepak Talwar, et al.. (2008). Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis (vol 45, pg 883, 2007). Ghent University Academic Bibliography (Ghent University). 108 indexed citations
20.
Pappas, Peter G., Robert F. Betts, Márcio Nucci, et al.. (2007). Micafungin versus Caspofungin for Treatment of Candidemia and Other Forms of Invasive Candidiasis. Clinical Infectious Diseases. 45(7). 883–893. 478 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Carola Arndt Breakdown of academic impact, for papers by S. Špánik Breakdown of academic impact, for papers by Juan Palou Breakdown of academic impact, for papers by I‐Shiow Jan Breakdown of academic impact, for papers by Tsiporah B. Shore Breakdown of academic impact, for papers by Hamdi Akan Breakdown of academic impact, for papers by David Bodensteiner Breakdown of academic impact, for papers by Chiara Cattaneo Breakdown of academic impact, for papers by Hans‐Heinrich Wolf Breakdown of academic impact, for papers by U. Jehn
Rankless by CCL
2026